Observations placeholder
Tasigna
Identifier
020178
Type of Spiritual Experience
Background
A description of the experience
Nilotinib (AMN107, trade name Tasigna, in the form of the hydrochloride monohydrate salt, is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia.
Adverse effects
Nilotinib has a number of adverse effects typical of anti-cancer drugs. These include headache, fatigue, gastrointestinal problems such as nausea, vomiting, diarrhea and constipation, muscle and joint pain, rash and other skin conditions, flu-like symptoms, and reduced blood cell count. Less typical side effects are those of the cardiovascular system, such as hypertension (high blood pressure), various types of arrhythmia, and prolonged QT interval. Nilotinib can also affect the body's electrolyte and glucose balance Though pulmonary-related adverse effects are rare when compared with imatinib and dasatinib, there is a case report of acute respiratory failure from diffuse alveolar hemorrhage in a patient taking nilotinib
On Dec, 30, 2016 13,842 people reported to have side effects when taking Tasigna.
Among them, 16 people (0.12%) have Hallucination
Time on Tasigna when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Gender of people who have Hallucination when taking Tasigna :
| Female | Male | |
| Hallucination | 17.65% | 82.35% |
On Jan, 29, 2016: 6,344 people reported to have side effects when taking Tasigna. Among them, 456 people (7.19%) have Death.
Time on Tasigna when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 31.33% | 44.58% | 8.43% | 8.43% | 7.23% | 0.00% | 0.00% |
Gender of people who have Death when taking Tasigna :
| Female | Male | |
| Death | 37.95% | 62.05% |
Age of people who have Death when taking Tasigna :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 0.00% | 0.00% | 0.71% | 4.59% | 9.54% | 13.43% | 21.20% | 50.53% |
Top conditions involved for these people :
- Chronic myeloid leukaemia (282 people, 61.84%)
- Gastrointestinal stromal tumour (28 people, 6.14%)
- Acute lymphocytic leukaemia (17 people, 3.73%)